Literature DB >> 7678117

Expression of an inaccessible P1.7 subtype epitope on meningococcal class 1 proteins.

E Wedege1, R Dalseg, D A Caugant, J T Poolman, L O Frøholm.   

Abstract

Dot-blot analysis of whole-cell suspensions of meningococci showed that 81% of B:15:P1.16 strains from patients reacted with a monoclonal antibody (MAb) against subtype P1.7. The remaining strains, which did not react on dot-blots or in ELISA, demonstrated the P1.7 subtype epitope on immunoblots after denaturation of the cells with sodium dodecyl sulphate. The monomeric class 1 proteins of the two P1.16 subtype variants had slightly different mol. wts, but bound the P1.7 antibody equally well. These results were explained by a deletion of three codons in the gene encoding the first variable region of the P1.16 class 1 protein. The deletion accounted for the non-exposure of the P1.7 epitope on native cells. Other patient strains, with subtypes P1.3, P1.9 or without any known subtype, also showed a binding site for the P1.7 MAb, which became available only after denaturation. Demonstration of inaccessible epitopes may have consequences for subtype designations and vaccine development.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678117     DOI: 10.1099/00222615-38-1-23

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  20 in total

1.  Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.

Authors:  E R van der Voort; P van der Ley; J van der Biezen; S George; O Tunnela; H van Dijken; B Kuipers; J Poolman
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Clonal analysis of the serogroup B meningococci causing New Zealand's epidemic.

Authors:  K H Dyet; D R Martin
Journal:  Epidemiol Infect       Date:  2006-04       Impact factor: 2.451

3.  Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.

Authors:  E Wedege; K Bolstad; A Aase; T K Herstad; L McCallum; E Rosenqvist; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

4.  Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.

Authors:  E Wedege; E A Høiby; E Rosenqvist; G Bjune
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

5.  Correlation between serological and sequencing analyses of the PorB outer membrane protein in the Neisseria meningitidis serotyping system.

Authors:  C T Sacchi; A P Lemos; A M Whitney; C A Solari; M E Brandt; C E Melles; C E Frasch; L W Mayer
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

Review 6.  Molecular techniques for the investigation of meningococcal disease epidemiology.

Authors:  M C Maiden; M Frosch
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

7.  Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997--1998: overview and implications for vaccine development.

Authors:  C T Sacchi; A P Lemos; T Popovic; J C De Morais; A M Whitney; C E Melles; L M Brondi; L M Monteiro; M V Paiva; C A Solari; L W Mayer
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

8.  Neisseria meningitidis native outer membrane vesicles containing different lipopolysaccharide glycoforms as adjuvants for meningococcal and nonmeningococcal antigens.

Authors:  Jerry C Nagaputra; Christine S Rollier; Manish Sadarangani; J Claire Hoe; Ojas Hrakesh Mehta; Gunnstein Norheim; Muhammad Saleem; Hannah Chan; Jeremy P Derrick; Ian Feavers; Andrew J Pollard; E Richard Moxon
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

9.  Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature.

Authors:  C T Sacchi; A P Lemos; M E Brandt; A M Whitney; C E Melles; C A Solari; C E Frasch; L W Mayer
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

Review 10.  Current status of meningococcal group B vaccine candidates: capsular or noncapsular?

Authors:  J Diaz Romero; I M Outschoorn
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.